Total trials
321
Active
42
Phase 3
17
Total enrollment
546,220
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Probiotic | — | — | — | — | — | 1 | |
| Gardasil 9 2 dose regimen | — | — | — | — | — | 1 | |
| Gardasil 9 3 dose regimen | — | — | — | — | — | 1 | |
| Gardasil 9 rescue dose | — | — | — | — | — | 1 | |
| prabotulinumtoxinA-xvfs | — | — | — | — | — | 1 | |
| Gabapentin | — | — | — | — | — | 2 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| Ensure Surgery Immunonutrition Shake | — | — | — | — | — | 1 | |
| Ensure Enlive Advanced Nutrition Shake | — | — | — | — | — | 1 | |
| Gardasil9 | — | — | — | — | — | 1 | |
| clonality analysis | — | — | — | — | — | 1 | |
| polymerase chain reaction | — | — | — | — | — | 1 | |
| protein analysis | — | — | — | — | — | 1 |
Next readouts
- 2026-04-15
- 2026-08
- 2026-09
- 2026-10
- 2027-06
- 2028-07
- 2030-03
- 2040-12
Top conditions
- HIV Infection10
- Depression9
- HIV Infections9
- Obesity8
- Multiple Myeloma7
- Cancer6
- Opioid Use Disorder6
- Hypertension6
Frequently asked questions about Boston Medical Center
- How many clinical trials does Boston Medical Center have on ClinicalTrials.gov?
- Boston Medical Center is listed as the lead sponsor on 321 clinical trials in ClinicalTrials.gov, 42 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Boston Medical Center's trials are in Phase 3?
- 17 of Boston Medical Center's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does Boston Medical Center focus on?
- Boston Medical Center's most-studied conditions on ClinicalTrials.gov are HIV Infection, Depression, HIV Infections, Obesity, Multiple Myeloma.
- When are Boston Medical Center's next clinical trial readouts?
- Boston Medical Center has 8 upcoming primary-completion readouts tracked here; the soonest is “An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen”, expected around 2026-04-15.